Given the current clinical use of aflibercept, a drug that targets VEGF, for the treatment of CRC resistant to OXA-based regimens [12], we hypothesised that changes in VEGF levels in the culture medium might be an important contributor to the difference in sensitivity between initial and subsequent treatment with OXA. Here, VEGFA is linked to colorectal carcinoma.